Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
ELNCF On Other Exchanges
All times are local (Market data is delayed by at least 15 minutes).

elan corp plc (ELNCF) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ELAN CORP PLC (ELNCF)

elan corp plc (ELNCF) Details

Elan Corporation, plc operates as a biotechnology company in the United States, Ireland, and internationally. The company primarily develops ELND005, an orally bioavailable small molecule in Phase II clinical trial being investigated for multiple neuropsychiatric indications on the basis of its proposed dual mechanism of action, which includes b-amyloid anti-aggregation and regulation of brain myo-inositol levels. It also develops ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder to delay the time to occurrence of mood episodes; and for the treatment of agitation/aggression in patients with moderate to severe Alzheimer’s disease. Elan Corporation, plc was founded in 1969 and is headquartered in Dublin, Ireland. As of December 18, 2013, Elan Corporation, plc operates as a subsidiary of Perrigo Company plc.

245 Employees
Last Reported Date: 06/28/13
Founded in 1969

elan corp plc (ELNCF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

elan corp plc (ELNCF) Key Developments

Elan Provides Group and Parent Earnings Guidance for the Year 2014

Elan expects to end 2014 with a profit on the back of 3% higher revenues of EUR 70 million ($79 million). Net profit is expected to be achieved both at group level and by the parent company.

Elan Plc Announces Resignation of Gary Kennedy as Director

Elan Corporation plc announced that following the completion of the acquisition by Perrigo Company plc of Elan Corporation plc on 18 December, 2013, Gary Kennedy, Greencore Chairman is no longer a director of Elan plc.

Elan Corporation, plc(ISE:DRX) dropped from S&P EUROPE 350

Elan Corporation, plc(ISE:DRX) dropped from S&P EUROPE 350


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELNCF:US $0.00 USD 0.00

ELNCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ELNCF.
View Industry Companies

Industry Analysis


Industry Average

Valuation ELNCF Industry Range
No financial data is available for ELNCF.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELAN CORP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at